Legrand Fatema A, Verardi Paulo H, Chan Kenneth S, Peng Yue, Jones Leslie A, Yilma Tilahun D
International Laboratory of Molecular Biology for Tropical Disease Agents, Department of Pathology, Microbiology, and Immunology, School of Veterinary Medicine, University of California, Davis, CA 95616, USA.
Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2940-5. doi: 10.1073/pnas.0409846102. Epub 2005 Feb 10.
In a continuing effort to develop safe and efficacious vaccine and immunotherapeutic vectors, we constructed recombinant vaccinia virus (rVV) vaccines lacking either the B13R (SPI-2) or the B22R (SPI-1) immune-modulating gene and coexpressing IFN-gamma. B13R and B22R are nonessential VV immune-modulating genes that have antiapoptotic and antiinflammatory properties with sequence homology to serine protease inhibitors (serpins). IFN-gamma is a cytokine with potent immunoregulatory, antineoplastic, and antiviral properties. We observed that these rVVs with a deletion in a serpin gene and expressing IFN-gamma replicated to high titers in tissue culture yet were avirulent in both immunocompromised and immunocompetent mice with no detectable viral replication in these animals. A single immunization elicited potent humoral, T helper, and cytotoxic T cell immune responses in mice despite the absence of any detectable virus replication in vivo. IFN-gamma coexpression and the inactivation of one or more VV immune-modulating genes provide an optimized method for increasing the safety while maintaining the efficacy of rVV vaccines. This strategy provides a method for developing highly safe and efficacious vaccines for smallpox and other diseases and immunotherapeutic vectors.
为持续研发安全有效的疫苗和免疫治疗载体,我们构建了缺失B13R(SPI-2)或B22R(SPI-1)免疫调节基因并共表达干扰素-γ的重组痘苗病毒(rVV)疫苗。B13R和B22R是痘苗病毒非必需的免疫调节基因,具有抗凋亡和抗炎特性,与丝氨酸蛋白酶抑制剂(丝氨酸蛋白酶抑制因子)有序列同源性。干扰素-γ是一种具有强大免疫调节、抗肿瘤和抗病毒特性的细胞因子。我们观察到,这些缺失丝氨酸蛋白酶抑制因子基因并表达干扰素-γ的rVV在组织培养中能复制至高滴度,但在免疫功能低下和免疫功能正常的小鼠中均无致病性,在这些动物体内未检测到病毒复制。尽管在体内未检测到任何可检测到的病毒复制,但单次免疫仍能在小鼠中引发强烈的体液免疫、辅助性T细胞免疫和细胞毒性T细胞免疫反应。干扰素-γ的共表达以及一个或多个痘苗病毒免疫调节基因的失活为提高rVV疫苗的安全性同时保持其有效性提供了一种优化方法。该策略为开发用于天花和其他疾病的高度安全有效的疫苗以及免疫治疗载体提供了一种方法。